

**Fiscal Year 2026 Congressionally Directed Medical Research Programs
Kidney Cancer Research Program (KCRP)
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Academy of Kidney Cancer Investigators – Early-Career Scholar Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942526KCRPAKCIECSA</p>	<p>Investigators within seven years of their last postdoctoral research position, clinical fellowship, or equivalent, by the full application submission deadline.</p> <ul style="list-style-type: none"> • Applications must include a letter attesting to the investigator’s eligibility. 	<ul style="list-style-type: none"> • Supports impactful kidney cancer research; and integrates new Early-Career Scholars (ECS) into a virtual academy providing intensive mentoring, national networking, research collaborations, and a peer group for early-career kidney cancer investigators. • ECSs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other significant obstacles are encouraged to apply. • Applications must identify a designated mentor who is an experienced kidney cancer investigator or clinician with a record of kidney cancer publications or funding. <ul style="list-style-type: none"> ○ A designated mentor may only mentor one scholar. ○ The designated mentor and the scholar may work or practice at different institutions. • Submission of a Letter of Intent is required prior to full application submission. • Preliminary data are required. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.2 million (M) for total costs.* • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): September 14, 2026 5:00 p.m. Eastern time</p> <p>Application: September 28, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Concept Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526KCRPCA</p>	<p>Investigators at all career levels, including postdoctoral fellows or equivalent.</p>	<ul style="list-style-type: none"> • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer. • Reviewers will be blinded to the identity of the Principal Investigator, collaborators and their organization(s). • Submission of a Letter of Intent is required prior to full application submission. • Preliminary data are not allowed. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$120,000 for total costs.* • The maximum period of performance is 1 year. 	<p>Pre-Application (Letter of Intent): July 28, 2026 5:00 p.m. Eastern time</p> <p>Application: August 11, 2026 11:59 p.m. Eastern time</p>
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526KCRPIDA</p>	<p>Investigators at or above the level of assistant professor, or equivalent.</p>	<ul style="list-style-type: none"> • Supports the development of innovative, high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes. • Partnering Principal Investigator Option: Supports meaningful and productive partnerships between two investigators, termed the Initiating PI and Partnering PI, collaborating on a single application. <ul style="list-style-type: none"> ◦ Each PI should provide equal intellectual input into the design and execution of the project. • Submission of a Letter of Intent is required prior to full application submission. • Preliminary data are required. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • Maximum allowable funding: <ul style="list-style-type: none"> ◦ Single PI: \$900,000 for total costs.* ◦ Partnering PI Option: \$1.2M for total costs.* • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): September 14, 2026 5:00 p.m. Eastern time</p> <p>Application: September 28, 2026 11:59 p.m. Eastern time</p>

*Total costs include direct and indirect costs.